Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...

Others operating in the NK cell engager area include Innate Pharma, in the clinic with Sanofi-partnered candidate IPH6101 for blood cancers, as well as GT Biopharma, Cytovia, and Compass Therapeutics.

Dr. Miller will speak to the mechanisms by which tri-specific engagers enhance NK cell activity, their unique ability to work synergistically with NK cells to improve cytotoxicity and increase ...

GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

GT Biopharma Dr. Miller will speak to the mechanisms by which tri-specific engagers enhance NK cell activity, their unique ability to work synergistically with NK cells to improve cytotoxicity and ...

GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE ® natural killer (“NK”) cell engager platform ...

GT Biopharma focuses on immuno-oncology therapies utilizing its proprietary TriKE® NK cell engager platform. GT Biopharma has secured approximately $0.7 million in gross proceeds through the ...

such as off-the-shelf TCR-guided T cell engager (TCR-TCE) therapies (MDG3010 and MDG3020), TCR-natural killer cell (TCR-NK) therapies and T cell receptor engineered T cell (TCR-T) therapies (MDG1015).